FDA Alerts Docs, Patients to Lack of Benefit With Tecentriq-Paclitaxel in Metastatic TNBC

NEW YORK – The US Food and Drug Administration alerted oncologists, researchers, and patients Tuesday afternoon that Genentech's atezolizumab (Tecentriq) plus paclitaxel did not benefit triple-negative breast cancer patients enrolled in the Phase III IMpassion131 trial.